Erythromycin Topical Gel USP, 2%, Net Wt 60 g tube, Rx only, Manufactured by: Teligent Pharma, In...

FDA Drug Recall #D-0851-2022 — Class II — April 21, 2022

Recall Summary

Recall Number D-0851-2022
Classification Class II — Moderate risk
Date Initiated April 21, 2022
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm McKesson Corporation dba McKesson Drug Company
Location Memphis, TN
Product Type Drugs
Quantity 5,640 tubes

Product Description

Erythromycin Topical Gel USP, 2%, Net Wt 60 g tube, Rx only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-053-68

Reason for Recall

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Distribution Pattern

Nationwide in the United States including Guam and the Northern Mariana Islands.

Lot / Code Information

Lot: 15723, Exp.: 06/30/2022

Other Recalls from McKesson Corporation dba McKesson Dru...

Recall # Classification Product Date
D-0848-2022 Class II Lidocaine Hydrochloride Topical Solution USP 4%... Apr 21, 2022
D-0847-2022 Class II Halobetasol Propionate Ointment 0.05% Net Wt., ... Apr 21, 2022
D-0849-2022 Class II Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net W... Apr 21, 2022
D-0850-2022 Class II Betamethasone Dipropionate Ointment USP, 0.05%*... Apr 21, 2022
D-0630-2021 Class III Levetiracetam Tablets USP, 250 mg UD 100 Tablet... May 26, 2021

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.